Peter Menziuso Named EVP and President, BD Interventional
Rhea-AI Summary
BD (NYSE: BDX) appointed Peter Menziuso as executive vice president and president of BD Interventional, effective June 1, 2026. He brings 30+ years of global healthcare leadership and previously led a $5 billion Johnson & Johnson Vision business across commercial, R&D, supply chain and other functions.
BD indicates his experience in market leadership, team building and operational excellence is expected to support continued growth and strong performance within BD Interventional.
AI-generated analysis. Not financial advice.
Positive
- Experienced leader appointed EVP and president of BD Interventional effective June 1, 2026
- Previously led a $5 billion global Johnson & Johnson Vision business
- More than 30 years of global healthcare leadership experience
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
BDX is down 0.69% with mixed peer action: ALC, RMD and BAX are negative, HOLX is flat and WST is positive. The varied moves point to stock-specific factors rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 07 | CFO appointment | Positive | +5.9% | Named long-time BD executive Vitor Roque as permanent chief financial officer. |
| May 07 | Earnings results | Positive | +5.9% | Reported Q2 FY2026 revenue growth, executed ASR, raised adjusted EPS guidance. |
| May 05 | AI partnership | Positive | -1.5% | Announced AI-powered medication management collaboration with Wellstar using BD platforms. |
| Apr 30 | Workforce awards | Positive | +2.6% | Received multiple industry recognitions for employee health, well-being and workforce programs. |
| Apr 29 | Product launch | Positive | -2.8% | Launched CentroVena One system for central line insertion with FDA 510(k) clearance. |
Recent BD headlines, especially executive appointments and earnings, have often coincided with positive price reactions, while some innovation-focused product and partnership news have seen short-term weakness.
Over the last few months, BD has combined strategic portfolio changes with leadership updates and product innovation. On May 7, the company reported $4.714 billion in Q2 FY2026 revenue and raised adjusted EPS guidance, alongside appointing a new CFO, both followed by gains of 5.87%. Earlier, AI-enabled medication management and a breakthrough vascular access launch highlighted innovation, though they saw short-term declines. Recognition for employee well-being on April 30 supported a modest rise. Today’s BD Interventional leadership appointment fits the ongoing management-refresh narrative.
Market Pulse Summary
This announcement highlights BD’s decision to appoint Peter Menziuso as executive vice president and president of BD Interventional, effective June 1, adding a leader with more than 30 years of healthcare experience and prior responsibility for a $5 billion business. In recent months, BD has paired leadership changes with portfolio and financial actions. Investors may watch how BD Interventional’s growth, margin trends and product pipeline execution evolve under this new leadership over coming quarters.
Key Terms
r&d technical
AI-generated analysis. Not financial advice.
Menziuso brings more than 30 years of global healthcare leadership experience and a strong track record of driving growth through disciplined execution. He most recently served as Company Group Chairman of Johnson & Johnson Vision, where he led a
Throughout his career, Menziuso has been recognized for strengthening market leadership, building high‑performing teams and translating strategy into sustained performance through commercial rigor and operational excellence. His global leadership experience, coupled with his customer obsession and ability to lead at scale position him well to accelerate execution and deliver continued growth for BD Interventional.
"BD Interventional has a strong track record of performance, and Peter is the right leader to build on that momentum and continue delivering results," said Tom Polen, chairman, CEO and president of BD. "Peter brings a strong combination of strategic leadership and operational discipline. He is grounded in delivering for customers and patients, building strong teams and driving consistent performance, positioning the business for sustained growth and continued strength across the portfolio."
About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media | Investors |
Megan Dubrowski | Shawn Bevec SVP, Investor Relations |
View original content to download multimedia:https://www.prnewswire.com/news-releases/peter-menziuso-named-evp-and-president-bd-interventional-302774280.html
SOURCE BD (Becton, Dickinson and Company)